Latency and interval therapy affect the evolution in metastatic colorectal cancer

While comparison of primary tumor and metastases has highlighted genomic heterogeneity in colorectal cancer (CRC), previous studies have focused on a single metastatic site or limited genomic testing. Combining data from whole exome and ultra-deep targeted sequencing, we explored possible evolutiona...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Scientific reports Ročník 10; číslo 1; s. 581
Hlavní autori:	Nikbakht, Hamid, Jessa, Selin, Sukhai, Mahadeo A., Arseneault, Madeleine, Zhang, Tong, Letourneau, Louis, Thomas, Mariam, Bourgey, Mathieu, Roehrl, Michael H. A., Eveleigh, Robert, Chen, Eric X., Krzyzanowska, Monika, Moore, Malcolm J., Giesler, Amanda, Yu, Celeste, Bedard, Philippe L., Kamel-Reid, Suzanne, Majewski, Jacek, Siu, Lillian L., Riazalhosseini, Yasser, Graham, Donna M.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London Nature Publishing Group UK 17.01.2020 Nature Publishing Group
Predmet:	45/22 45/23 631/67/69 692/4017 Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - genetics DNA Copy Number Variations DNA Mutational Analysis Evolution Female Gene Frequency Gene Regulatory Networks Genetic Heterogeneity Heterogeneity High-Throughput Nucleotide Sequencing Humanities and Social Sciences Humans Latency Lesions Liver Liver Neoplasms - genetics Liver Neoplasms - secondary Lung cancer Lung Neoplasms - genetics Lung Neoplasms - secondary Male Metastases Metastasis multidisciplinary Mutation Science Science (multidisciplinary) Time Factors Tumors Whole Exome Sequencing
ISSN:	2045-2322, 2045-2322
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	While comparison of primary tumor and metastases has highlighted genomic heterogeneity in colorectal cancer (CRC), previous studies have focused on a single metastatic site or limited genomic testing. Combining data from whole exome and ultra-deep targeted sequencing, we explored possible evolutionary trajectories beyond the status of these mutations, particularly among patient-matched metastatic tumors. Our findings confirm the persistence of known clinically-relevant mutations (e.g., those of RAS family of oncogenes) in CRC primary and metastases, yet reveal that latency and interval systemic therapy affect the course of evolutionary events within metastatic lesions. Specifically, our analysis of patient-matched primary and multiple metastatic lesions, developed over time, showed a similar genetic composition for liver metastatic tumors, which were 21-months apart. This genetic makeup was different from those identified in lung metastases developed before manifestation of the second liver metastasis. These results underscore the role of latency in the evolutionary path of metastatic CRC and may have implications for future treatment options.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23
ISSN:	2045-2322 2045-2322
DOI:	10.1038/s41598-020-57476-y